Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 14, 2005 - Issue 11
Submit an article Journal homepage
137
Views
42
CrossRef citations to date
0
Altmetric
Review

Benign prostatic hyperplasia: an insight into current investigational medical therapies

Atul Tiwari Urology and Metabolic Group, NDDR, Ranbaxy Research Laboratories, Gurgaon-122001, Haryana, India. [email protected] . E-mail:[email protected]
,
N S Krishna Urology and Metabolic Group, NDDR, Ranbaxy Research Laboratories, Gurgaon-122001, Haryana, India. [email protected] . E-mail:[email protected]
,
Kamna Nanda Urology and Metabolic Group, NDDR, Ranbaxy Research Laboratories, Gurgaon-122001, Haryana, India. [email protected] . E-mail:[email protected]
&
Anita Chugh Urology and Metabolic Group, NDDR, Ranbaxy Research Laboratories, Gurgaon-122001, Haryana, India. [email protected] . E-mail:[email protected]
Pages 1359-1372 | Published online: 28 Oct 2005

Bibliography

  • MARCELLI M, CUNNINGHAM GR: Hormonal signaling in prostatic hyperplasia and neoplasia. I OM Endocrinol Metab. (1999) 84:3463–3468.
  • CAINE M: The present role of a-adrenergic blockers in the treatment of benign prostatic hypertrophy. Urol. (1986) 136(1):1–4.
  • HIEBLE JP, CAINE M, ZALAZNIK E: hi vitro characterization of the a-adrenoceptors in human prostate. Eur. Pharmacol (1985) 107(2):111–117.
  • CAINE M, RAZ S, ZEIGLER M: Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br. J. Um]. (1975) 47(2):193–202.
  • LEPOR H, GUP DI, BAUMANN M, SHAPIRO E: Laboratory assessment of terazosin and a-1 blockade in prostatic hyperplasia. Urology (1988) 32(6):21–26.
  • GUP DI, SHAPIRO E, BAUMANN M, LEPOR H: Contractile properties of human prostate adenomas and the development of infravesical obstruction. Prostate (1989) 15(2):105–114.
  • LEPOR H, SHAPIRO E: Characterization of al adrenergic receptors in human benign prostatic hyperplasia. Um]. (1984) 132(6):1226–1229.
  • YAMADA S, ASHIZAWA N, USHIJIMA H, NAKAYAMA K, HAYASHI E, HONDA K: a-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy. I Pharmacol Exp. Ther. (1987) 242(1):326–330.
  • KOBAYASHI S, TANG R, SHAPIRO E, LEPOR H: Characterization and localization of prostatic al adrenoceptors using radioligand receptor binding on slide-mounted issue section. J. Um]. (1993) 150(6):2002–2006.
  • FURUYA S, KUMAMOTO Y, YOKOYAMA E, TSUKAMOTO T, IZUMI T, ABIKO Y: a-adrenergic activity and urethral pressure in prostatic zone in benign prostatic hypertrophy. I Urol. (1982) 128(4):836–839.
  • DJAVAN B, CHAPPLE C, MILANI S, MARBERGER M: State of the art on the efficacy and tolerability of aradrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology (2004) 64(6):1081–1088.
  • MILANI S, DJAVAN B: Lower urinary symptoms suggestive of benign prostatic hyperplasia: latest update on a-adrenoceptor antagonists. RIU (2005) 95:29–36.
  • •The article highlights the importance of a-blockers as the first-choice treatment option in LUTS/BPH.
  • LEE M: Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. Am. J. Health Syst. Pharm. (2003) 60(14):1426–1439.
  • JACOBSEN SJ, JACOBSON DJ, GIRMAN CJ et al.: Natural history of prostatism: risk factors for acute urinary retention. J. Urol. (1997) 158(2):481–487.
  • KMD 3213, KAD 3213, silodosin. Drugs R D (2004) 5(1):50–51.
  • WYLLIE MG: Uroselectivity: end of the road? RIU Int. (2003) 92:141–142.
  • DIOKNO AC: Benign changes in the prostate with ageing. BE J. Um]. (1998) 82 (Suppl. 1):44–46.
  • GRAYHACK JT, KOZLOWSKI JM, LEE C: The pathogenesis of benign prostatic hyperplasia: a proposed hypothesis and critical evaluations. J. Um]. (1998) 160:2375–2380.
  • BUTTYAN R, SHABSIGH A, PERLMAN H, COLOMBEL M: of apoptosis in the prostate gland by androgenic steroids. Trends Endocrinol Metab. (1999) 10(2):47–54.
  • ISAACS JT: Antagonistic effect of androgen on prostatic cell death. Prostate (1984) 5(5):545–557.
  • CARSON C, RITTMASTER R: The role of dihydrotestosterone in benign prostatic hyperplasia. Urology (2003) 61(Suppl. 4A):2–7.
  • GEORGE FW, CARR BR, NOBLE JF, WILSON JD: 5-a reduced androgens in the human fetal testis. J. Clin. Metab. (1987) 64(3):628–630.
  • SPAN PN, SCHALKEN JA, SWEEP FG, SMALS AG: Identification and partial characterization of two steroid 5 a-reducatse isozymes in the canine prostate. Prostate (1998) 34(3):222–230.
  • PELLETIER G, LUU-THE V, XF, LAPOINTE H, LABRIE F: Localization by in situ hybridization of steroid 5 a-reductase isozyme gene expression in the human prostate and preputial skin. J. Urol. (1998) 160:582–587.
  • BARTSCH G, RITTMASTER RS, KLOCKER H: Dihydrotestosterone and the concept of 5a-reductase inhibition in human benign prostatic hyperplasia. World J. Urol. (2002) 19:413–425.
  • •This article provides an overview of endocrine-regulated prostate growth and a clinical perspective of mono and dual 5a-reductase inhibitors in the management of BPH.
  • GLASSMAN DT, CHON JK, BORKOWSKI A, JACOBS SC, KYPRIANOU N: Combined effect of terazosin and finasteride on apoptosis, cell proliferation and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate (2001) 46(1):45–51.
  • ANDRIOLE GL, KIRBY R: Safety and tolerability of the dual 5a-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur. Urol. (2003) 44:82–88.
  • ROEHRBORN CG, BOYLE P, JC et al.: Efficacy and safety of a dual inhibitor of 5-a-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology (2002) 60 (3):434–441.
  • McCONNELL JD, BRUSKEWITZ R, WALSH P et al: The effect of finasteride on the risk of acute urinary retention and the for surgical treatment among men with benign prostatic hyperplasia. N Engl. J. Med. (1998) 338 (9):557–563.
  • •The clinical study demonstrates the efficacy of fmasteride in a long-term placebo-controlled trial for the treatment of BPH.
  • LEPOR H, WILLIFORD WO, BARRY MJ et al: For the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group: the efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl. I Med. (1996) 335:533–539.
  • KIRBY R, BOYLE P, ROEHRBORN C: Results of PREDICT (Prospective Randomized European Doxazosin and Combination) study of medical therapy for BPH. Br. J. Urol. (1999) 83:83 (Abstract).
  • CALAIS DA SILVA F, MARQUIS P, DESCHASEAUX P, GINESTE JL, CAUQUIL J, PATRICK DL: Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur. Urol. (1997) 31:272–280.
  • SUN ZY, FENG J, QUI XD, WU HY, ZHENG WJ, TU ZH: Reversible long-term toxicity of epristeride in beagle dogs. Toxicol Appl. Phannacol (1999) 154(2):145–152.
  • BERREVOETS CA, UMAR A, BRINKMANN AO: Antiandrogens: selective androgen receptor modulators. Mol Cell. Endocrinol (2002) 198:97–103.
  • •The article highlights the mechanism of action of antiandrogens and SAWS.
  • BERGER BM, NAADIMUTHU A, BODDY A et al: The effect of zanosterone, a steroidal androgen receptor antagonist, in men with benign prostatic hyperplasia. The Zanosterone Study Group../. Urol. (1995) 154(3):1060–1064.
  • CONN PM, CROWLEY WF Jr: Gonadotropin-releasing hormone and its analogs. Ann. Rev Med. (1994) 45:391–405.
  • KARTEN MJ, RIVIER JE: Gonadotropin-releasing hormone analog design - structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr. Rev. (1986) 7:44–66.
  • EVANS CP, FLESHNER N, FITZPATRICK JM, ZLOTTA AR: An evidence-based approach to understanding the pharmacological class effect in the of prostatic diseases. RIU Int. (2005) 95:743–749.
  • •The article sets out the principles of evidence-based medicine (EBM) as a main factor among various treatment choices that are available for the management of BPH and prostate cancer.
  • SCHLEGEL PN, BRENDLER CB: Management of urinary retention due to benign prostatic hyperplasia using leutenizing hormone-releasing hormone agonist. Urology (1989) 34(2):69–72.
  • BOSCH RJ, GRIFFITHS DJ, BLOM JH, SCHROEDER FH: Treatment of benign prostatic hyperplasia by androgen deprivation: effects on prostate size and urodynamic parameters. J. Urol. (1989) 141(1):68–72.
  • OESTERLING JE: LHRH agonists. A nonsurgical treatment for benign prostatic hyperplasia. Andra (1991) 12(6):381–388.
  • ERI LM, TVETER KJ: A prospective, placebo-controlled study of the leuteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. Urol. (1993) 150(2):359–364.
  • PALLAS P, PARADA G: Treatment of acute urinary retention caused by benign prostatic hypertrophy with an LH-RH agonist (goserelin). Actas Urol. Esp. (1995) 19(2):118–122.
  • CROOK T, SHERIDAN WP: Development of GnRH antagonists for prostate cancer: New approaches to treatment. Oncologist (2000) 5:162–168.
  • WILLIAMS MB, HERNANDEZ J, THOMPSON I: Leuteinizing hormone-releasing hormone agonist effects on skeletal muscle: how hormonal therapy in prostate cancer affects muscular strength. Urol. (2005) 173(4):1067–1071.
  • WECKERMANN D, HARZMANN R: Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur. Urol. (2004) 46:279–284.
  • •The article provides a good clinical comparison of gonadorelin agonists versus antagonists.
  • HUIRNE JA, LAMBALK CB:-releasing-hormone-receptor antagonists. Lancet (2001) 358:1793–1803.
  • •The article highlights the chemistry, pharmacokinetics, pharmacodynamics, safety, tolerability and therapeutic applications of LHRH antagonists.
  • COMARU-SCHALLY AM, W, SCHALLY AV, COLCOLOUGH M, MONGA M: Efficacy and safety of leutenizing hormone-releasing antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. I Clin. Endocrinol Metab. (1998) 83:3826–3831.
  • COSTELLO LC, FRANKLIN RB: Testosterone and prolactin regulation of metabolic genes and citrate metabolism of prostate epithelial cells. Horn. Metab. Res. (2002) 34(8):417–424.
  • •The study demonstrates the testosterone and prolactin regulation of citrate metabolism in prostate cells.
  • COSTELLO LC, FRANKLIN RB: Novel role of rinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate (1998) 35(4):285–296.
  • COSTELLO LC, FRANKLIN RB: Citrate metabolism of normal and malignant prostate epithelial cells. Urology (1997) 50(1):3–12.
  • STONER E: Three-year safety and efficacydata on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology (1994) 43:284–289.
  • PEEHL DM, SKOWRONSKI RJ, LEUNG GK, WONG ST, STAMEY TA, FELDMAN D: Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Res. (1994) 54:805–810.
  • CRESCIOLI C, MAGGI M, GB et al: Effect of vitamin D3 analogue on keratinocyte growth factor-induced cell proliferation in benign prostatic hyperplasia. j Clin. Endocrinol Metab. (2000) 85(7):2576–2583.
  • •The study demonstrates the role of growth factors, especially mitogenic KGF, in the pathophysiology of BPH. The antiproliferative and proapoptotic effects of vitamin D3 analogues in BPH cells have been demonstrated.
  • DJONOV V, BALL RK, GRAF S et al: Transforming growth factor-133 is expressed in nondividing basal epithelial cells in normal human prostate and benign prostatic hyperplasia, and is no longer detectable in prostate carcinoma. Prostate (1997) 31:103–109.
  • BARRACK ER: TGF-13 in prostate cancer: a growth inhibitor that can enhance. Prostate (1997) 31(1):61–70.
  • SKOWRONSKI RJ, PEEHL DM, FELDMAN D: Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology (1993) 132: 1952-1960.
  • WU-WONG JR, TIAN J, D: Vitamin D analogs as therapeutic agents: a clinical study update. Curr. Opin. Invest. Drugs (2004) 5(3):320–326.
  • CRESCIOLI C, MORELLI A, ADORINI L: Human bladder as a novel target for vitamin D receptor ligands. Clin. Endocrinol Metab. (2005) 90(2):962–972.
  • •The study demonstrates the positive effects of BXL-628 on prostate overgrowth and bladder overactivity due to the presence of VDRs in human bladder.
  • EMONS G, GRONDKER C, GONTHERT AR, WESTPHALEN S, KARANAGH J, VERSCHRAEGEN C: GnRH antagonists in the treatment of gynecological and breast cancers. Endocrine-Related Cancer (2003) 10:291–299.
  • MAUDSLEY S, DAVIDSON L, PAWSON AJ, CHAN R, DE MATURANA RL, MILLAR RP: Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupled state of the type I GnRH receptor. Cancer Res. (2004) 64(20)7533–7544.
  • WHITTINGTON K, ASSINDER S, GOULD M, NICHOLSON H: Oxytocin, oxytocin-associated neurophysin and the oxytocin receptor in the human prostate. Cell Tissue Res. (2004) 318(2):375–382.
  • NICHOLSON HD: Oxytocin: a paracrineregulator of prostatic function. Rev Reprod. (1996) 1(2):69–72.
  • REVERSI A, RIMOLDI V, MORROCCO T et al.: The oxytocin receptor antagonist atosiban inhibits cell growth via a 'biased agonise mechanism. ./. Biol. Chem. (2005) 280 (16):16311–16318.
  • ZHANG XH, FILLIPI S, VIGNOZZI L et al.: Identification, localization and functional in vitro and in vivo activity of oxytocin receptor in the rat penis. (2005) 184(3):567–576.
  • STEINER MS, GINGRICH JR: Gene therapy for prostate cancer. Where are we now?' Urol. (2000) 164(01121–1136.
  • SELKIRK SM: Gene therapy in clinical medicine. Postgrad. Med. J. (2004) 80(948)560–570.
  • LOWE FC, DREIKORN K, A et al.: Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate (1998) 37(3):187–193.
  • BOYLE P, ROBERTSON C, LOWE F, ROEHRBORN C: Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BIU Int. (2004) 93(6):751–756.
  • DEBRUYNE F, KOCH G, BOYLE P et al: Comparison of a phytotherapeutic agent (Permixon) with an a-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. Prog. Urol. (2002) 12:384–392.
  • AUA PRACTICE GUIDELINES COMMITTEE: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J. Urol. (2003) 170(2):530–547.
  • FOLEY CL, KIRBY RS: 5 a-reductase inhibitors: what's new? Curr. Opin. Urol. (2003) 13(1):31–37.
  • McDONALD H, HUX M, BRISSON M, BERNARD L, NICKEL JC: An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia. Can. J. Urol. (2004) 11(02327–2340.
  • SAVAGE SJ, SPUNGEN AM, GALEA G, BRITANICO J, VAPNEK JM: Combination medical therapy for symptomatic benign prostatic hyperplasia. Can. J. Urol. (1998) 5(3):578–584.
  • DEBRUYNE FM, JARDIN A, COLLOID et al: Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur. Urol. (1998) 34(3):169–175.
  • LEPOR H, WILLIFORD WO, MJ, HAAKENSON C, JONES K: The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Hyperplasia Study Group. J Ural. (1998) 160(4):1358–1367.
  • KIRBY RS, ROEHRBORN C, BOYLE P et al.: Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology (2003) 61(1):119–126.
  • McCONNELL JD, ROEHRBORN CG, BAUTISTA OM et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl. J. Med. (2003) 349:2387–2398.
  • •The clinical trial illustrates the safety and reduction in the risk of AUR and need for invasive therapy with long-term combination therapy of doxazosin and finasteride compared with monotherapies.
  • DI SILVERIO F, BOSMAN C, SALVATORI M et al.: Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Eur. Ural. (2005) 47(1):72–78.
  • BALDWIN KC, GINSBERG PC, ROEHRBORN CG, HARKAWAY RC: Discontinuation of a-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia. Urology (200 1) 58(2):203–209.
  • BARKIN J, GUIMARAES M, JACOBI G, PUSHKAR D, TAYLOR S, VIERSSEN TRIP OB: a-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5a-reductase inhibitor dutasteride. Eur. Ural. (2003) 44(4):461–466
  • ATHANASOPOULOS A, K, GIANNITSAS K, FISFIS J, PERIMENIS P, BARBALIAS G: Combination treatment with an a-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Ural. (2003) 169(6):2253–2256.
  • LEE JY, KIM HW, LEE SJ, KOH JS, SUH HJ, CHANCELLOR MB: Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJUInt. (2004) 94(6):817–820.
  • PARTIN JV, ANGLIN IE, N: Quinazoline-based ai-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF-13 signaling and IxBa induction. BE J Cancer. (2003) 88(10):1615–1621.
  • AUSTIN PF, COOK BL, RA, MANSON SR, COPLEN DE, WEINTRAAB SJ: Inhibition of mitogenic signaling and induction of apoptosis in human bladder smooth muscle cells treated with doxazosin. J Ural. (2004) 172(4):1662–1665.

Websites

  • http://www.iddb.com Drugs Database website.
  • http://www.medscape.com/viewarticle/ 480500-term GnRH agonist use may increase risk of fractures.
  • http://www.thresholdpharm.com Company website highlighting the information about lonidamine (TH-070).
  • http://www.urotoday.org Pharmaceutical announces positive results from the TH-070 Phase II study in treatment of BPH.
  • http://www.urologytimes.com/ urologytimes/article/ articleDetail.jsp?id=177454 BPH data reveal key findings on epidemiology and treatment.
  • http://www.urologytimes.com//content/printjsp?id=179171 Study documents the effect of LUTS on erectile function.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.